• Alumis Inc. has reported first-quarter 2026 results alongside past Phase 3 data showing strong efficacy for its oral TYK2 inhibitor envudeucitinib in moderate-to-severe plaque psoriasis, while revenue declined to US$1.74 million and net loss reached US$93.05 million.
• A key insight is that Alumis is pairing these psoriasis results with plans for a New Drug Application in late 2026 and potentially pivotal systemic lupus erythematosus data in the third quarter of 2026, positioning envudeucitinib as the centerpiece of a broader TYK2 franchise while reassessing its lonigutamab program.
• We’ll now examine how Alumis’ late-stage envudeucitinib progress, including the planned psoriasis NDA filing, shapes the company’s broader investment narrative.

Invest in the nuclear renaissance through our list of 87 elite nuclear energy infrastructure plays powering the global AI revolution.

What Is Alumis' Investment Narrative?

To own Alumis today, you really have to believe in envudeucitinib as a platform asset rather than focus on current financials. The latest quarter reminded investors that this is still a loss-making R&D story, with revenue falling to US$1.74 million and net loss at US$93.05 million, even as the share price has risen very sharply over the past year. What arguably matters more near term is that the company backed up its psoriasis Phase 3 success with detailed data and reaffirmed a late 2026 NDA filing and potentially pivotal SLE readout in the third quarter of 2026. That strengthens the near term catalyst path, but also concentrates risk in a single TYK2 program while lonigutamab is reassessed and ongoing cash burn and past dilution remain front of mind.

However, investors should also weigh how long Alumis might fund losses before envudeucitinib decisions arrive. In light of our recent valuation report, it seems possible that Alumis is trading beyond its estimated value.

Exploring Other Perspectives

Three Simply Wall St Community fair values span roughly US$2 to US$40 per share, underlining how widely views differ. Against that backdrop, the envudeucitinib NDA and SLE data timing become key milestones that could reshape how you think about Alumis’ risk and reward profile.

Explore 3 other fair value estimates on Alumis - why the stock might be worth as much as 74% more than the current price!

Reach Your Own Conclusion

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Alumis research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.
• Our free Alumis research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Alumis' overall financial health at a glance.

Seeking Other Investments?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Capitalize on the AI infrastructure supercycle with our selection of the 42 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.